TENAX THERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0.0 | $0.0 | — | — | — |
| Operating income | -$56.4 | -$19.5 | -$8.2 | $11.1 | -$32.7 |
| Net income | -$52.6 | -$17.6 | -$7.7 | $11.0 | -$32.5 |
| Cash Flow Statement | |||||
| Free cash flow | — | — | — | -$11.4 | -$10.9 |
Shares outstanding 37.4M · Free float 76.9%
Annual filing data through FY ended December 31, 2025; float as of September 15, 2026.